JOP20210111A1 - نظائر عامل gdf15 وطرق استخدامه في تقليل وزن الجسم و/أو تخفيض امتصاص الطعام - Google Patents
نظائر عامل gdf15 وطرق استخدامه في تقليل وزن الجسم و/أو تخفيض امتصاص الطعامInfo
- Publication number
- JOP20210111A1 JOP20210111A1 JOP/2021/0111A JOP20210111A JOP20210111A1 JO P20210111 A1 JOP20210111 A1 JO P20210111A1 JO P20210111 A JOP20210111 A JO P20210111A JO P20210111 A1 JOP20210111 A1 JO P20210111A1
- Authority
- JO
- Jordan
- Prior art keywords
- body weight
- food intake
- gdf15
- methods
- reducing food
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862769675P | 2018-11-20 | 2018-11-20 | |
| PCT/IB2019/059945 WO2020104948A1 (en) | 2018-11-20 | 2019-11-19 | Gdf15 analogs and methods for use in decreasing body weight and/or reducing food intake |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20210111A1 true JOP20210111A1 (ar) | 2021-05-19 |
Family
ID=70773869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2021/0111A JOP20210111A1 (ar) | 2018-11-20 | 2021-05-19 | نظائر عامل gdf15 وطرق استخدامه في تقليل وزن الجسم و/أو تخفيض امتصاص الطعام |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20220315633A1 (enExample) |
| EP (1) | EP3883960A4 (enExample) |
| JP (2) | JP2022513098A (enExample) |
| KR (1) | KR20210094584A (enExample) |
| CN (2) | CN113474363A (enExample) |
| AU (2) | AU2019383019A1 (enExample) |
| BR (1) | BR112021009225A2 (enExample) |
| CA (1) | CA3120236A1 (enExample) |
| EA (1) | EA202191424A1 (enExample) |
| IL (1) | IL283189A (enExample) |
| JO (1) | JOP20210111A1 (enExample) |
| MX (1) | MX2021005908A (enExample) |
| PH (1) | PH12021551119A1 (enExample) |
| SG (1) | SG11202104952PA (enExample) |
| WO (1) | WO2020104948A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY205905A (en) | 2018-10-22 | 2024-11-20 | Janssen Pharmaceutica Nv | Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof |
| ES3061099T3 (en) | 2019-10-04 | 2026-03-31 | Amgen Inc | Use of gdf15 for treating cardiometabolic syndrome and other conditions |
| IL310535A (en) * | 2021-08-10 | 2024-03-01 | Byomass Inc | Anti-gdf15 antibodies, compositions and uses thereof |
| WO2023154953A1 (en) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9131966B2 (en) * | 2013-03-11 | 2015-09-15 | DePuy Synthes Products, Inc. | Vertebral manipulation assembly |
| EP3157947A1 (en) * | 2014-06-23 | 2017-04-26 | Novartis AG | Hsa-gdf-15 fusion polypeptide and use thereof |
| US20190000923A1 (en) * | 2015-12-22 | 2019-01-03 | Novartis Ag | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| US10336812B2 (en) * | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| MY205905A (en) * | 2018-10-22 | 2024-11-20 | Janssen Pharmaceutica Nv | Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof |
-
2019
- 2019-11-19 CN CN201980089716.4A patent/CN113474363A/zh active Pending
- 2019-11-19 CA CA3120236A patent/CA3120236A1/en active Pending
- 2019-11-19 US US17/309,328 patent/US20220315633A1/en active Pending
- 2019-11-19 KR KR1020217018694A patent/KR20210094584A/ko not_active Ceased
- 2019-11-19 AU AU2019383019A patent/AU2019383019A1/en not_active Abandoned
- 2019-11-19 WO PCT/IB2019/059945 patent/WO2020104948A1/en not_active Ceased
- 2019-11-19 CN CN202511010324.8A patent/CN121818901A/zh active Pending
- 2019-11-19 MX MX2021005908A patent/MX2021005908A/es unknown
- 2019-11-19 EA EA202191424A patent/EA202191424A1/ru unknown
- 2019-11-19 SG SG11202104952PA patent/SG11202104952PA/en unknown
- 2019-11-19 JP JP2021527918A patent/JP2022513098A/ja not_active Withdrawn
- 2019-11-19 BR BR112021009225-0A patent/BR112021009225A2/pt unknown
- 2019-11-19 EP EP19886438.1A patent/EP3883960A4/en active Pending
-
2021
- 2021-05-13 IL IL283189A patent/IL283189A/en unknown
- 2021-05-14 PH PH12021551119A patent/PH12021551119A1/en unknown
- 2021-05-19 JO JOP/2021/0111A patent/JOP20210111A1/ar unknown
-
2025
- 2025-02-07 JP JP2025019347A patent/JP2025081388A/ja active Pending
- 2025-04-02 AU AU2025202337A patent/AU2025202337A1/en active Pending
- 2025-07-03 US US19/260,242 patent/US20260159562A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3883960A1 (en) | 2021-09-29 |
| MX2021005908A (es) | 2021-09-08 |
| EA202191424A1 (ru) | 2021-08-24 |
| JP2025081388A (ja) | 2025-05-27 |
| AU2019383019A1 (en) | 2021-06-03 |
| JP2022513098A (ja) | 2022-02-07 |
| US20260159562A1 (en) | 2026-06-11 |
| PH12021551119A1 (en) | 2021-11-22 |
| US20220315633A1 (en) | 2022-10-06 |
| AU2025202337A1 (en) | 2025-04-24 |
| KR20210094584A (ko) | 2021-07-29 |
| EP3883960A4 (en) | 2022-11-09 |
| CN113474363A (zh) | 2021-10-01 |
| WO2020104948A1 (en) | 2020-05-28 |
| IL283189A (en) | 2021-06-30 |
| SG11202104952PA (en) | 2021-06-29 |
| CA3120236A1 (en) | 2020-05-28 |
| BR112021009225A2 (pt) | 2021-10-05 |
| CN121818901A (zh) | 2026-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021551119A1 (en) | Gdf15 analogs and methods for use in decreasing body weight and/or reducing food intake | |
| PH12019501216A1 (en) | New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists | |
| MX2020011427A (es) | Derivados del polipeptido insulinotropico dependiente de la glucosa (gip) y usos de estos. | |
| PH12018501882A1 (en) | Binding proteins and methods of use thereof | |
| MX2021003475A (es) | Metodos de purificacion de proteinas. | |
| MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
| MX2016010951A (es) | Proteinas de fc multimericas. | |
| NZ754051A (en) | Novel antibodies and uses thereof | |
| MY182593A (en) | Composition containing chitin and digestible proteins | |
| NZ757500A (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| EA201892619A1 (ru) | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 | |
| MX2019006427A (es) | Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip. | |
| MX2024003743A (es) | Inmunoglobulinas de union a agrecano. | |
| EP3939606A3 (en) | Improved methods and compounds for eliminating immune responses to therapeutic agents | |
| EA201692279A1 (ru) | Способ уменьшения иммуногенности белка и пептида | |
| MY199876A (en) | Anti-pacap antibody | |
| MX2018008793A (es) | Combinacion farmaceutica o nutricional que comprende beta-hidroxi-betametilbutirato. | |
| MX2017006639A (es) | Metodos y composiciones para preservar la masa corporal magra y promover la perdida de grasa durante la perdida de peso. | |
| PH12017500156A1 (en) | Angiopoietin-like 4 antibodies and methods of use | |
| PH12015501870B1 (en) | Nutritional compositions containing a peptide component with adiponectin stimulating properties and uses thereof | |
| TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
| MX2017000878A (es) | Peptidos marinos y nucleotidos de pescado, composiciones y sus usos para reducir la glucosa en la sangre. | |
| EP4249503A3 (en) | Vsig8-based chimeric proteins | |
| MX2017006638A (es) | Metodos y composiciones para el incremento de la masa corporal magra y minimizar la ganancia de grasa corporal y el control del peso. | |
| MX2018011512A (es) | Uso de insulina para promover el vaciamiento gástrico. |